Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...

A new study found that Ozempic's main ingredient may treat people with type 1 diabetes, control blood sugar, and lose weight.

A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with ...

Would you get a one-time genetic modification such that you'd never have to take a GLP-1 drug for weight loss ever again?

Ozempic ® (semaglutide) injection 0.25 mg, 0.5 mg, 1.0 mg or 2.0 mg is a once-weekly GLP-1 RA indicated, along with diet and exercise, to improve blood sugar (glucose) in adults with type 2 ...

CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a randomized trial showed.

CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.

Semaglutide (Ozempic) improves blood sugar control and weight loss in people with type 1 diabetes and obesity using insulin pumps, new study shows.

Novo Nordisk NVO announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that Ozempic’s (once-weekly ...

NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...